New hope for rare lung cancer mutations: targeted pill after surgery

NCT ID NCT05546866

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 29 times

Summary

This study tests the drug osimertinib in people with non-small cell lung cancer that has certain uncommon gene changes (EGFR mutations). Participants take the pill after their tumor is completely removed by surgery. The goal is to see if the drug helps keep the cancer from coming back. About 51 adults will take part in this phase 2 trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Research Site

Beijing, 100730, China
Research Site

Chengdu, 610000, China
Research Site

Chengdu, 610041, China
Research Site

Fuzhou, 350011, China
Research Site

Guangzhou, 510080, China
Research Site

Kunming, 650118, China
Research Site

Ningbo, 315010, China
Research Site

Shijiazhuang, 050051, China
Research Site

Suzhou, 215006, China
Research Site

Tianjin, 300060, China

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER